N-Alkylated aziridines are easily-prepared, potent, specific and cell-permeable covalent inhibitors of human β-glucocerebrosidase.

β-Glucocerebrosidase deficiency leads to Gaucher disease and is a potential marker of Parkinson's disease. We have identified N-octyl conduritol aziridine as a potent and specific covalent inactivator of GBA1 in living cells. This compound is a promising lead towards a positron emission tomography probe intended to image GBA1 activity.

[1]  D. Krainc,et al.  Development of targeted therapies for Parkinson’s disease and related synucleinopathies , 2014, Journal of Lipid Research.

[2]  S. Withers,et al.  Fluoro-glycosyl acridinones are ultra-sensitive active site titrating agents for retaining β-glycosidases. , 2014, Chemical communications.

[3]  S. Stroobants,et al.  Synthesis and in vivo preclinical evaluation of an (18)F labeled uPA inhibitor as a potential PET imaging agent. , 2014, Nuclear medicine and biology.

[4]  G. Halliday,et al.  Glucocerebrosidase deficits in sporadic Parkinson disease , 2014, Autophagy.

[5]  F. Platt,et al.  β-Glucosidase 2 (GBA2) Activity and Imino Sugar Pharmacology* , 2013, The Journal of Biological Chemistry.

[6]  Andrew G. Watts,et al.  Mechanism-Based Covalent Neuraminidase Inhibitors with Broad-Spectrum Influenza Antiviral Activity , 2013, Science.

[7]  Sylvain Houle,et al.  Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET , 2013, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  J. Jiang,et al.  Novel activity-based probes for broad-spectrum profiling of retaining β-exoglucosidases in situ and in vivo. , 2012, Angewandte Chemie.

[9]  F. Platt,et al.  The cell biology of disease: lysosomal storage disorders: the cellular impact of lysosomal dysfunction. , 2012, The Journal of cell biology.

[10]  H. Overkleeft,et al.  Tuning the leaving group in 2-deoxy-2-fluoroglucoside results in improved activity-based retaining β-glucosidase probes. , 2012, Chemical communications.

[11]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[12]  Daniel R. Albaugh,et al.  Time-Dependent Inhibition and Estimation of CYP3A Clinical Pharmacokinetic Drug-Drug Interactions Using Plated Human Cell Systems , 2012, Drug Metabolism and Disposition.

[13]  S. Withers,et al.  Tailoring the specificity and reactivity of a mechanism-based inactivator of glucocerebrosidase for potential therapeutic applications. , 2011, Angewandte Chemie.

[14]  J. Koricheva,et al.  A Meta-Analysis of Predation Risk Effects on Pollinator Behaviour , 2011, PloS one.

[15]  D. Chan,et al.  Aberrant glycosylation associated with enzymes as cancer biomarkers , 2011, Clinical Proteomics.

[16]  G. A. van der Marel,et al.  Ultrasensitive in situ visualization of active glucocerebrosidase molecules. , 2010, Nature chemical biology.

[17]  E. Sidransky,et al.  Glucocerebrosidase is present in α-synuclein inclusions in Lewy body disorders , 2010, Acta Neuropathologica.

[18]  S. Withers,et al.  Imaging of enzyme replacement therapy using PET , 2010, Proceedings of the National Academy of Sciences.

[19]  P. Mistry,et al.  The risk of Parkinson’s disease in type 1 Gaucher disease , 2010, Journal of Inherited Metabolic Disease.

[20]  R. Pires,et al.  Recommendations on diagnosis, treatment, and monitoring for Gaucher disease. , 2009, The Journal of pediatrics.

[21]  S. Withers,et al.  Non-Stick Sugars: Synthesis of Difluorosugar Fluorides as Potential Glycosidase Inactivators , 2009 .

[22]  A. Baici,et al.  3‐Fluoro‐2,4‐dioxa‐3‐phosphadecalins as Inhibitors of Acetylcholinesterase. A Reappraisal of Kinetic Mechanisms and Diagnostic Methods , 2009, Chemistry & biodiversity.

[23]  S. Withers,et al.  Covalent inhibitors of glycosidases and their applications in biochemistry and biology. , 2008, Glycobiology.

[24]  L. Delbaere,et al.  Structural, Functional and Calorimetric Investigation of MosA, a Dihydrodipicolinate Synthase from Sinorhizobium meliloti L5–30, does not Support Involvement in Rhizopine Biosynthesis , 2008, Chembiochem : a European journal of chemical biology.

[25]  L. Juillerat-Jeanneret,et al.  Glycosylation pathways as drug targets for cancer: glycosidase inhibitors. , 2006, Mini reviews in medicinal chemistry.

[26]  M. Piel,et al.  Efficient alkali iodide promoted 18F-fluoroethylations with 2-[18F]fluoroethyl tosylate and 1-bromo-2-[18F]fluoroethane , 2003 .

[27]  N. Volkow,et al.  Strategy for the Formation of Parametric Images under Conditions of Low Injected Radioactivity Applied to PET Studies with the Irreversible Monoamine Oxidase a Tracers [11C]Clorgyline and Deuterium-Substituted [11C]Clorgyline , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[28]  N. Volkow,et al.  Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[29]  D. M. Ryan,et al.  Rational design of potent sialidase-based inhibitors of influenza virus replication , 1993, Nature.

[30]  S. Withers,et al.  Conduritol aziridine: a new mechanism-based glucosidase inactivator. , 1989, Biochemical and biophysical research communications.

[31]  C. D. Arnett,et al.  Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET. , 1987, Science.

[32]  N. Radin,et al.  A revised fluorometric assay for Gaucher's disease using conduritol-beta-epoxide with liver as the source of Beta-glucosidase. , 1980, Clinica chimica acta; international journal of clinical chemistry.

[33]  M. Node,et al.  Inhibitors against glycosidases as medicines. , 2009, Current topics in medicinal chemistry.